Olanzapine
Olanzapine, 2-Methyl-10-(4-methylpiperazin-1-yl)-4H-3-thia-4,9-diazabenzo[f]azulene
C17H20N4S, M=312.44 g/mol
atypical antipsychotic
Trade Mark: Zyprexa®
Application
Treatment of schizophrenia and bipolar mania. Initial dose 10 mg, thereafter 20 mg. The maximum level is reached after 5-8 hours, half-life 21 up to 54 hours.
Contraindications
Do not use with older dementia patients as well as cases of glaucoma.
Interactions
Accelerated metabolism with simultaneous use of Carbamazepine, slowed down metabolisms with Fluvoxamine.
Adverse Effects
Substantial weight gain with increased diabetic risk, since Olanzapine intervenes in the insulin metabolism.
Analytics
Therapeutic levels: 0.02 up to 0.03 µg/ml (serum/plasma).
Custom Search
